World · India Bureau
Solara Active Pharma surges on stellar Q2 turnaround, H1 profits surge
Shares of Solara Active Pharma Sciences jumped 16% after the company swung to significant profitability in the first half of the fiscal year. The pharmaceutical firm posted consolidated net profit of ₹44.70 crore in H1FY27, a more than 100-fold increase from just ₹0.42 crore in the same period last year.
LSN India ·
Solara Active Pharma Sciences demonstrated a sharp operational turnaround in the second quarter of fiscal 2027, reporting consolidated net profit of ₹28.59 crore compared to a loss of ₹9.29 crore in the corresponding quarter of the previous year. The Mumbai-listed specialty pharmaceutical company's strong performance lifted investor sentiment, with share prices surging 16% on the earnings announcement.
The company's first-half performance reflected even more dramatic improvement, with cumulative net profit reaching ₹44.70 crore during H1FY27 against a modest profit of ₹0.42 crore in H1FY26. This represents a more than 100-fold increase year-over-year, signaling a substantial recovery in the firm's financial trajectory.
The Q2 results mark a significant milestone for Solara Active Pharma, which had been grappling with profitability challenges in the prior year. The turnaround underscores the company's efforts to optimize operations and strengthen its market position in the competitive pharmaceutical sector.
Analysts attributed the improvement to better operational efficiency and increased demand for the company's active pharmaceutical ingredients and specialty pharmaceutical products. The results add Solara Active Pharma to the list of companies posting robust earnings as the Indian pharmaceutical industry continues its expansion.